Floatz logo

AMSACRINE

Leukemia, Nonlymphocytic, Acute

University Hospital, ToulouseSmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

685 Active assets in the Leukemia, Nonlymphocytic, Acute cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
ETOPOSIDE
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3BBB

View all 50 →

Same molecule, other indications

AMSACRINE is also rated in:

leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
Acute Myeloid LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →